Results from a first-in-human phase I study of HDM201 in patients with advanced wild-type TP53 solid tumors and acute leukemia indicated a consistent safety profile and noted preliminary activity, particularly in acute myeloid leukemia (AML). This evidence concerns the gene TP53 and acute myeloid leukemia.